Mr. Stephen Van Deventer reports

PREVECEUTICAL WELCOMES STEPHEN GLOVER AS CORPORATE ADVISOR

Preveceutical Medical Inc. has appointed Stephen (Steve) Glover as corporate adviser, effective on 24 May, 2025.

Stephen Van Deventer, chief executive officer of Preveceutical, commented: "We are honoured to welcome Stephen Glover as our corporate adviser. Stephen's proven leadership in biopharma, combined with his expertise in corporate strategy, commercialization and financial management, makes him an invaluable addition to our team. His track record of building and transforming organizations aligns seamlessly with Preveceutical's mission to advance groundbreaking therapies."

About Mr. Glover

Mr. Glover is an accomplished executive with over three decades of leadership experience in the biopharma industry. Currently, he serves as chairman and chief executive officer of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company focused on innovative treatments for inflammatory and kidney diseases. Mr. Glover has successfully led multiple organizations, securing over $500-million in capital and creating more than $7-billion in shareholder value.

Previously, Mr. Glover was chairman of Ambrx, overseeing its $2-billion acquisition by Johnson & Johnson. He also co-founded Coherus BioSciences, where he developed strategic partnerships valued at over $300-million. Mr. Glover's operational expertise spans commercialization, integrated product development and governance, having overseen the launch of over 25 products in multiple therapeutic areas.

In addition to his extensive executive experience, Mr. Glover serves on the board of publicly traded companies, including as chairman of PDS Biotechnology, a Nasdaq Stock Market company, and the University of Miami Coulter Foundation, bringing insights into audit, compensation and governance practices.

Mr. Glover remarked on his appointment: "I am excited to join Preveceutical and work with the leadership team to expand the application and growth of their exciting Sol-Gel program in multiple therapeutic categories. The growth of the nasal delivery market over the next few years represents a great opportunity to develop new products for significant unmet medical needs and provide patients with a better option for treatments in many disease areas."

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual-gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.